OR WAIT 15 SECS
July 27, 2015.
Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) has announced that it has signed a definitive agreement to acquire the generics business of Allergan (Dublin, Ireland) in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion. The Israeli firm simultaneously announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Amsterdam, The Netherlands). http://www.tevapharm.com/news_media/